Document link: Evidence Summary (Proponents may submit appeals to hta@doh.gov.ph until 28 June 2022 using the prescribed form accessible via Topic Nomination.)
Preliminary Recommendation for the Inclusion of Potassium Citrate 1620 mg (15 mEq) Tablet in the PNF
Document link: HTAC Preliminary Recommendation of Potassium Citrate 15mEq Tablet (Proponents may submit appeals to hta@doh.gov.ph until 27 April 2022.) Document Preview:
Preliminary Recommendation for the Inclusion of Rituximab 1400 mg/11.7 mL Solution for Subcutaneous (SC) Injection for the Treatment of Non-Hodgkin’s Lymphoma
Document link: Evidence Summary on Subcutaneous Rituximab for the Treatment of Non-Hodgkin’s Lymphoma (Proponents may submit appeals to hta@doh.gov.ph until 18 March 2022.) Document Preview:
Preliminary Recommendation for the Inclusion of Vasopressin 20 IU/mL (IM/IV)
Document link: Preliminary Recommendation on Vasopressin (Proponents may submit appeals to hta@doh.gov.ph until 25 February 2022.) Document Preview:
Preliminary Recommendation for the Non-Inclusion of Pertuzumab for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Document link: Preliminary Recommendation on Pertuzumab for HER2+ breast cancer (Proponents may submit appeals to hta@doh.gov.ph until 04 February 2022.) Document Preview: